Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.6B
55M shares
52-week range
$41.02 – $83.98
98% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.08B | $934.2M | $1.04B | $1.02B | $1.15B | $1.25B | $1.39B |
| Cost of revenue | $372.5M | $360.4M | $339.5M | $329.4M | $314.6M | $382.3M | $382.6M | $448.2M |
| Gross profit | $734.5M | $723.8M | $594.8M | $706.0M | $707.2M | $771.3M | $870.9M | $939.9M |
| Gross margin | 66.4% | 66.8% | 63.7% | 68.2% | 69.2% | 66.9% | 69.5% | 67.7% |
| R&D | $146.0M | $197.1M | $152.9M | $183.4M | $155.8M | $193.8M | $182.5M | $185.8M |
| Operating income | −$248.1M | −$171.6M | −$273.9M | −$784.0K | −$76.8M | −$68.5M | $129.1M | $199.4M |
| EBITDA | −$167.7M | $119.2M | $6.3M | −$6.3M | $30.9M | $38.5M | $202.5M | −$129.5M |
| Net income | −$189.4M | −$157.6M | −$348.8M | −$135.8M | −$86.2M | $17.5M | $63.2M | −$242.5M |
| Net margin | -17.1% | -14.5% | -37.3% | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% |
| EPS (diluted) | -3.91 | -3.22 | -7.06 | -2.68 | -1.61 | 0.32 | 1.16 | -4.45 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.5B | $4.25 | $4.24–$4.26 | 6 |
| 2027 | $1.6B | $4.63 | $4.50–$4.91 | 6 |
| 2028 | $1.7B | $5.09 | $4.78–$5.37 | 4 |
| 2029 | $2.1B | $7.10 | $6.96–$7.27 | 2 |
Forward consensus · source: Financial Modeling Prep
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
www.livanova.comNo one on the platform currently holds LIVN.
No tracked institution reports a position in LIVN as of their last filing.
No one on the platform has traded LIVN yet.
| $3.5B |
| — |
| IRONDisc Medicine, Inc. | $74.50 | -0.37% | $2.8B | — |
| LEGNLegend Biotech Corporation | $29.39 | +2.44% | $5.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 3.6× sales vs its 2.4× historical median P/S.
Fair value ≈ $55.13 · price $83.06 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$LIVN Livanova - A medical technology company that sells products for Cardiopulmonary & Neuromodulation. Only 380 watchers on ST. Last ER was a beat. 4.5B MC & smallish float.
View on StockTwits ↗$LIVN Share Price: $73.35 Contract Selected: Dec 18, 2026 $70 Calls Buy Zone: $9.35 – $11.55 Target Zone: $17.22 – $21.04 Potential Upside: 74% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$VVOS $LIVN As you can see under the section "Other Players": These are the only companies listed on Nasdaq. LIVN has a market cap of $4B, and VVOS has a market cap of $10M. https://www.marketsandmarkets.com/Market-Reports/united-states-sleep-apnea-devices-market-220821026.html
View on StockTwits ↗$LIVN Current Stock Price: $70.43 Contracts to trade: $70.0 LIVN May 15 2026 Call Entry: $1.25 Exit: $1.79 ROI: 43% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$LIVN reported 0.98 EPS and 263.30 revenue for Q1. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm
View on StockTwits ↗$LIVN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.41 up 106.82% YoY • Reported revenue of $362.3M up 14.34% YoY • LivaNova raised its full-year 2026 constant-currency revenue growth guidance to 7.0% to 8.0% and adjusted diluted EPS to $4.20 to $4.30, while maintaining adjusted free cash flow guidance at $160M to $180M.
View on StockTwits ↗Wall St is expecting 0.90 EPS for $LIVN Q1 [Reporting 05/06 BMO] http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$LIVN Current Stock Price: $70.26 Contracts to trade: $70.0 LIVN Mar 20 2026 Call Entry: $0.95 Exit: $1.53 ROI: 61% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$LIVN reported 0.86 EPS and 360.90 revenue for Q4. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm
View on StockTwits ↗$LIVN: LivaNova beats by $0.04, beats on revs; guides FY26 EPS above consensus, revs in-line https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260225061017LIVN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
View on StockTwits ↗$LIVN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.57 down -44.66% YoY • Reported revenue of $360.9M up 12.15% YoY • LivaNova PLC expects full-year 2026 revenue to grow 6.0% to 7.0% on a constant-currency basis. Adjusted diluted earnings per share is projected between $4.15 and $4.25, with adjusted free cash flow in the $160 million to $180 million range.
View on StockTwits ↗$LIVN LivaNova operates medical devices with exposure to cardiac and neuromodulation markets. Growth depends on procedural volumes and innovation pipeline. Margin improvement supports long-term outlook.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.